- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 22, 2017 P2, N=202, Active, not recruiting, Trial primary completion date: Nov 2020 --> Nov 2019 Trial primary completion date: Dec 2017 --> Apr 2020
- |||||||||| samotolisib (LY3023414) / Eli Lilly
Trial primary completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 21, 2017 P1, N=130, Recruiting, Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: Jul 2017 --> Mar 2018
- |||||||||| letrozole / Generic mfg.
Enrollment closed, Enrollment change, Trial initiation date: Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment (clinicaltrials.gov) - Mar 21, 2017 P2/3, N=35, Active, not recruiting, Trial primary completion date: Jul 2017 --> Mar 2018 Recruiting --> Active, not recruiting | N=50 --> 35 | Initiation date: Feb 2013 --> Oct 2013
- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 3, 2017 P2, N=202, Active, not recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 23, 2017 P2, N=42, Active, not recruiting, Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: May 2019 --> Sep 2019 Trial primary completion date: Apr 2017 --> Apr 2018
- |||||||||| Ibrance (palbociclib) / Pfizer
Enrollment closed: Palbociclib and FES PET (clinicaltrials.gov) - Feb 15, 2017 P2, N=15, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| letrozole / Generic mfg.
Enrollment closed, Trial primary completion date: PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) - Jan 17, 2017 P4, N=20, Active, not recruiting, Trial primary completion date: May 2017 --> May 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jun 2017
|